Charles Schwab Investment Management Inc. Raises Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Charles Schwab Investment Management Inc. increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 753,363 shares of the specialty pharmaceutical company's stock after purchasing an additional 40,968 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.36% of Supernus Pharmaceuticals worth $27,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pacer Advisors Inc. increased its position in Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company's stock worth $54,655,000 after buying an additional 403,028 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock worth $46,218,000 after purchasing an additional 74,438 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Supernus Pharmaceuticals by 1.1% during the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company's stock valued at $23,163,000 after buying an additional 7,833 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Supernus Pharmaceuticals by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock valued at $14,449,000 after buying an additional 27,134 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Supernus Pharmaceuticals by 4.0% during the 4th quarter. Principal Financial Group Inc. now owns 296,732 shares of the specialty pharmaceutical company's stock valued at $10,730,000 after buying an additional 11,321 shares in the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,104 shares of company stock worth $440,263. Corporate insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Stock Performance

SUPN stock traded up $0.08 on Thursday, hitting $32.11. 20,225 shares of the company's stock were exchanged, compared to its average volume of 459,595. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a 50 day moving average price of $35.90 and a two-hundred day moving average price of $35.11. The stock has a market cap of $1.79 billion, a P/E ratio of 29.96 and a beta of 0.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.